01—Abstract
Summary
Summary of the 10-Q filed August 1, 2023. Cited figures are marked; the original filing is the authoritative source.
Exelixis, Inc. reported financial results for the quarter ended June 30, 2023 in this Form 10-Q.
Total revenues for the second quarter were $469.8 milliona, up from $419.4 million a year earlier, driven by net product revenues of $409.6 million (CABOMETYX $403.3 million). Income from operations was $77.8 million, and net income was $81.2 million, or $0.25 per share basic and diluted, compared with $70.7 million, or $0.22 per share, in the second quarter of 2022. Research and development expenses rose to $232.6 million and selling, general and administrative expenses rose to $141.7 million.
For the six months ended June 30, 2023, total revenues were $878.6 millionb and net income was $121.2 million. The company ended the quarter with $2.1 billion in cash, cash equivalents and investments, and states it expects its resources to fund operations for at least 12 months. During the six months, Exelixis repurchased $127.0 million of common stock under a $550 million program authorized in March 2023, leaving approximately $423.0 million available.
Operating cash flow for the six months was $205.4 millionc. The filing highlights legal and competitive risk around CABOMETYX. On July 18, 2023, the company entered into a settlement and license agreement with Teva that grants Teva a license to market a generic version in the U.S. beginning January 1, 2031, if approved by the FDA.
Litigation against MSN and Cipla over generic ANDA filings remains ongoing, and the filing states that a generic launch could significantly decrease U.S. CABOMETYX revenues. The filing also notes that the Inflation Reduction Act and other drug pricing initiatives could affect future revenues.
02—Key points
Key Highlights
- Total revenues of $469.8 million for Q2 2023, up from $419.4 million in Q2 2022; net product revenues were $409.6 million.
- Net income of $81.2 million, or $0.25 per share basic and diluted, for Q2 2023, versus $70.7 million, or $0.22 per share, a year earlier.
- Research and development expenses rose to $232.6 million from $199.5 million, and SG&A expenses rose to $141.7 million from $122.8 million.
- Cash, cash equivalents and investments totaled $2.1 billion at June 30, 2023, and the company expects its resources to sustain operations for at least 12 months.
- The company repurchased $127.0 million of common stock in the first half of 2023 under a $550 million authorization, with approximately $423.0 million remaining.
- Teva settlement agreement (July 18, 2023) grants Teva a U.S. license for a generic CABOMETYX beginning January 1, 2031, subject to FDA approval; MSN and Cipla patent litigation continues.
- Phase 3 trial CONTACT-02 primary PFS results are anticipated in the second half of 2023; COSMIC-313 OS analysis is expected in the second half of 2023.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q2 FY2024, Exelixis kept $0.17.
- Revenue$469.8M100.0%
- Cost of revenue−$17.7M3.8%
- Gross profit$452.1M96.2%
- Operating costs−$374.3M79.7%
- Operating income$77.8M16.6%
- Interest, other & tax$3.3M0.7%
- Net income$81.2M17.3%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2024filed August 1, 2023Financial Statements
Q2 FY2024 against Q2 FY2023
| Line item | Q2 FY2024Q2 FY2023 | Change |
|---|---|---|
| Revenue | $469.85M$419.43M | +12.0% |
| Cost of Revenue | $17.70M$13.48M | +31.3% |
| Gross Profit | $452.14M$405.95M | +11.4% |
| R&D Expenses | $232.57M$199.48M | +16.6% |
| SG&A Expenses | $141.72M$122.76M | +15.4% |
| Operating Expenses | $392.00M$335.72M | +16.8% |
| Operating Income | $77.85M$83.71M | −7.0% |
| Net Income | $81.18M$70.67M | +14.9% |
| EPS (Basic) | $0.25$0.22 | +13.6% |
| EPS (Diluted) | $0.25$0.22 | +13.6% |
| Shares Outstanding (Basic) | 324.20M321.12M | +1.0% |
| Shares Outstanding (Diluted) | 327.31M324.90M | +0.7% |
05—Questions
Frequently Asked Questions
What drove the increase in revenue this quarter?
Net product revenues rose to $409.6 million from $347.0 million, which the filing attributes primarily to a 10% increase in CABOMETYX units sold, including from the first-line combination with OPDIVO, and a 9% increase in average net selling price. License revenues were $52.7 million, down from $57.5 million, while collaboration services revenues fell to $7.5 million from $14.9 million.
How is the company's profitability trending?
Income from operations was $77.8 million in Q2 2023, down from $83.7 million a year earlier, as operating expenses grew faster than revenue. Net income increased to $81.2 million from $70.7 million, helped by interest income of $22.5 million versus $4.8 million a year earlier.
What is the threat from generic CABOMETYX?
The filing states that generic versions of CABOMETYX are subject to ANDAs filed by MSN, Teva and Cipla. The company states that a generic launch could significantly decrease U.S. CABOMETYX revenues and materially harm its business. Under the July 2023 Teva settlement, Teva may market a generic version in the U.S. starting January 1, 2031, if approved by the FDA. A bench trial for MSN II is scheduled for October 2023.
How is the company returning capital to shareholders?
In March 2023 the Board authorized repurchases of up to $550 million of common stock before the end of 2023. The company repurchased 6,607,962 shares for $127.0 million through June 30, 2023, leaving about $423.0 million available under the program.
06—Continue